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Induction of the kynurenine pathway (KP) of tryptophan (TRP) catabolism has been 
 proposed to contribute to T cell dysfunction during human/simian immunodeficiency 
virus (SIV) infection via depletion of local TRP levels and production of immunomodu-
latory KP metabolites. However, while changes in TRP and KP metabolites have been 
observed in plasma, their levels in lymphoid tissues and levels of enzymes downstream 
of indoleamine 2,3-dioxygenase (IDO1) have been relatively unexplored. We used our 
SIV-infected pigtailed macaque model to analyze longitudinal changes in KP metabolites 
and enzymes by gas chromatography/mass spectrometry and NanoString nCounter 
gene expression analysis, respectively, in spleen and blood compared to changes 
previously established in brain and CSF. We found that TRP levels were remarkably 
stable in tissue sites despite robust depletion in the circulating plasma and CSF. We also 
demonstrated that intracellular TRP reserves were maintained in cultured cells even in the 
presence of depleted extracellular TRP levels. Kynurenine (KYN), 3-hydroxykynurenine, 
quinolinic acid, and the KP enzymes all displayed highly divergent patterns in the sites 
examined, though IDO1 expression always correlated with local KYN/TRP ratios. Finally, 
we demonstrated by fluorescence-activated cell sorting that myeloid dendritic cells and 
cells of monocytic lineage were the highest producers of IDO1 in chronically infected 
spleens. Overall, our study reveals insights into the tissue-specific regulation of KP 
enzymes and metabolites and, in particular, highlights the multiple mechanisms by which 
cells and tissues seek to prevent TRP starvation during inflammation.
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Abbreviations: APC, antigen-presenting cell; ART, anti-retroviral therapy; cART, combination anti-retroviral therapy; 
d-1MT, 1-methyl-d-tryptophan; DC, dendritic cell; FACS, fluorescence-activated cell sorting; GCMS, gas chromatography 
mass spectrometry; GCN2, general control non-derepressible 2, also known as EIF2AK4; HAAO, 3-hydroxyanthranilate-
3,4-dioxygenase, also known as 3HAO; HIV, human immunodeficiency virus; IDO1, indoleamine 2,3-dioxygenase; IFN, 
interferon; KMO, kynurenine 3-monooxygenase, also known as kynurenine 3-hydroxylase; KP, kynurenine pathway; KYN, 
kynurenine; KYN/TRP, kynurenine/tryptophan ratio; KYNU, kynureninase; mDC, myeloid dendritic cell; MNC, mononuclear 
cell; NAD+, nicotinamide adenine dinucleotide; pDC, plasmacytoid dendritic cell; PBMC, peripheral blood mononuclear cell; 
QPRT, quinolinate phosphoribosyltransferase; QUIN, quinolinic acid; SIV, simian immunodeficiency virus; SOCS3, suppressor 
of cytokine signaling 3; TRP, tryptophan; TTS, tryptophanyl tRNA synthetase; TYR, tyrosine; 3HANA, 3-hydroxyanthranilic 
acid; 3HK, 3-hydroxykynurenine.
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inTrODUcTiOn
Induction of the kynurenine pathway (KP) of tryptophan (TRP) 
catabolism is thought to play a major role in immune dysfunction 
in human immunodeficiency virus (HIV)-infected individuals, 
even those on combination anti-retroviral therapy (cART) (1–8). 
While the KP is an important source of the cellular cofactor 
NAD+, TRP is a rare essential amino acid, and small changes 
in TRP metabolism can have major consequences. For example, 
reducing extracellular TRP levels suppresses proliferation of 
actively dividing cells via accumulation of uncharged TRP–tRNAs 
and subsequent activation of the GCN2 stress kinase pathway 
(9). This mechanism could suppress patients’ T cell responses 
to HIV or secondary opportunistic infections. In addition to 
the consequences of TRP depletion, increased TRP catabolism 
down the KP also leads to generation of metabolites that have 
immunomodulatory capabilities, which include prevention of T 
cell proliferation [kynurenine (KYN) and picolonic acid] (10); 
conversion of naïve T cells or proinflammatory Th17 cells into 
regulatory T cells following interactions at the aryl hydrocarbon 
receptor, which may increase susceptibility to opportunistic 
infections at mucosal surfaces [KYN and 3-hydroxy anthranilic 
acid (3HANA)] (2, 11); and direct apoptosis of activated T cells 
(3HANA and cinnabarinic acid) (12, 13).
Thus, both the generation of immunosuppressive KP metabo-
lites and depletion of TRP during HIV/simian immunodeficiency 
virus (SIV) infection could contribute to peripheral HIV patho-
genesis. However, several key questions remain unanswered in 
the field. For example, while TRP and KP metabolites in the 
blood of HIV-infected patients have been extensively measured 
(1, 2, 5–8, 14), whether or not these measurements in the circula-
tion accurately reflect changes occurring in lymphoid tissues is 
unknown, leading to assumptions that this is a major mechanism 
of suppression in lymphoid tissues. Additionally, while expres-
sion of the rate-limiting enzyme indoleamine 2,3-dioxygenase 1 
(IDO1) has been repeatedly examined in the context of HIV/SIV 
infection, the regulation of downstream enzymes of the KP has 
been relatively unexplored.
To explore these questions, we measured the longitudinal 
kinetics of KP enzymes and metabolites by multiplexed mRNA 
(Nanostring nCounter) and GC-MS/MS assays in spleen and 
plasma from an accelerated pigtailed macaque model of HIV 
infection in which animals develop clinical symptoms of AIDS 
within 3  months (15). Our results show that individual cells 
(macrophages) and tissues (spleen) actively maintain internal 
TRP levels while depleting extracellular and circulating (plasma) 
TRP during KP activation. These data suggest that immuno-
suppressive effects of IDO1 in tissues are more likely a result 
of immunomodulatory KP metabolites than TRP starvation, 
representing a potential paradigm shift in our understanding of 
IDO1-mediated immunosuppression in HIV pathogenesis.
MaTerials anD MeThODs
animals
Macaque experiments performed in this study utilized archived 
samples from juvenile pigtailed macaques (Macaca nemestrina) 
that were either mock inoculated or inoculated intravenously 
with a neurotropic clone (SIV/17E-Fr) and an immunosup-
pressive swarm (SIV/DeltaB670), as previously described (16). 
Animals were euthanized during various stages of disease: acute 
(7, 10, 14 days p.i.), asymptomatic (21 dpi), and chronic infec-
tion (35, 42, 56, and 84 dpi). Animals euthanized prior to their 
planned euthanasia date due to presentation of clinical symptoms 
(17) were grouped with 84 dpi animals as SIV terminal (“T” in 
figures). Blood draws were taken prior to infection as well as on 
days 7, 10, 14, 21, 28, and every 2 weeks thereafter postinfection. 
All animals were euthanized in accordance with federal guide-
lines and institutional policies. Macaques were perfused with 
sterile PBS while under deep anesthesia, and tissues were col-
lected and flash frozen. All animal studies were approved by the 
Johns Hopkins Animal Care and Use Committee, and all animals 
were humanely treated in accordance with federal guidelines and 
institutional policies.
Macrophage cell culture
Pigtailed macaque peripheral blood mononuclear cells (PBMCs) 
were cultured in macrophage differentiation media (MDM) 
containing DMEM supplemented with 20% human AB serum 
(Gemini Bio Products), 50  ng/mL recombinant human mac-
rophage colony-stimulating factor (R&D Systems), 2 mM sodium 
pyruvate (Sigma), 2 mM l-glutamine (Life Technologies), 1 mM 
HEPES buffer (Life Technologies), and 20  µg/mL gentamicin 
(Gibco) for 7  days until mature macrophages were visible. 
Macrophages were then washed 3× with PBS and switched to 
MDM with 10% human AB serum. Twenty-five nanograms per 
milliliter of rhesus IFNγ (R&D Systems) or 400  U/mL human 
IFNβ1a (PBL Interferon Source) were added in duplicate wells 
for each time point. After 0, 24, 48, and 72 h, supernatants were 
saved for KP metabolite analysis, and cells were washed and then 
harvested with gentle scraping for KP metabolite and IDO1 gene 
expression analysis. Metabolites were normalized to controls at 
each time point as well as to tyrosine (TYR), which does not 
change during HIV infection (18), to control for minor variations 
in cell number that could affect metabolism.
Metabolite extraction from spleen
A 3-mm punch was taken from perfused, snap-frozen spleen 
tissue from SIV-infected pigtailed macaques. Punches were 
weighed and diluted 1/20 (weight/volume) with cold 0.1% ascor-
bic acid and sonicated with a tip sonicator three to five times at 
70% amplitude for 5 s each, in batches on ice. Residual debris was 
removed by brief tabletop centrifugation prior to extraction of 
metabolites. On ice, 50 µL of spleen homogenates (of the origi-
nal 1/20 homogenates for metabolite measurement, or diluted 
further for a final of 1/2,000 in 0.1% ascorbic acid for amino acid 
measurement) were spiked with 50 µL of a solution containing 
the following heavy standards: [2H5] TRP (1 µM, CDN Isotopes, 
QC, Canada), [2H2] TYR (1 µM, CDN Isotopes, QC, Canada), 
[2H6] KYN (5 µM, custom synthesis from Sigma-Aldrich Isotec), 
and [2H3] quinolinic acid (0.05  µM, custom synthesis from 
Synfine, ON, Canada). Fifty microliters of ice cold acetone were 
added to homogenates and samples were centrifuged at 20,000 g 
for 5 min to precipitate protein. Eighty percent (120/150 μL) of 
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the acetone supernatant was transferred to a new microcentri-
fuge tube, to which 50  µL of a 2:5 ratio methanol:chloroform 
was added. Samples were centrifuged at 20,000 g for 10 min, and 
60% (80/134 μL) of the aqueous layers were transferred to glass 
vials. The aqueous solution was dried and then derivatized with 
120  µL of 2,2,3,3-pentafluoro-1-propanol (Sigma-Aldrich) and 
135  µL of pentafluoropropionic anhydride (Sigma-Aldrich) by 
heating at 75°C for 30 min. Derivatized samples were dried and 
stored at −80°C.
Metabolite extractions from Plasma and 
Macrophage cell culture supernatants
Metabolite extractions from plasma and cell culture superna-
tants were identical to spleen with the following modifications: 
for plasma samples, 2 µL of cell-free plasma were diluted 1/25 
with 0.1% ascorbic acid in a final volume of 50 µL for metabolite 
and amino acid measurements. For cell culture supernatants, 
cell-free supernatants were diluted 1/2 in 0.2% ascorbic acid for 
metabolites and 1/100 in 0.1% ascorbic acid for amino acids, 
all in a final volume of 50 µL. The heavy standard mixture for 
plasma and cell culture supernatant matrices required higher 
concentrations for two metabolites: 15 µM instead of 5 µM for 
[2H6] KYN, and 0.2 µM instead of 0.05 µM for [2H3] quinolinic 
acid. All other heavy standards were kept at 1  µM. Acetone 
extraction supernatants were dried down directly on a speedvac 
without methanol/chloroform extraction and then derivatized 
as above.
Metabolite extraction from In Vitro 
Macrophage cells
Macrophage cell pellets were resuspended in 100 µL of 0.1% ascor-
bic acid and sonicated 2× for 3 s each at 30% amplitude with a tip 
sonicator on ice. Fifty microliters of this homogenate were used as 
the starting material for intracellular amino acid and metabolite 
measurements. The heavy standard concentrations were identical 
to those used for plasma and cell culture supernatant samples. 
The acetone precipitation, methanol/chloroform extraction, and 
derivatization for the macrophage cell pellets were otherwise 
performed in an identical manner to the protocol used for spleen 
homogenates.
gc/Ms/Ms analysis of amino acids and 
KP Metabolites
Dried samples were resuspended in 50 µL ethyl acetate, with the 
exception of the in vitro macrophage lysates, which were resus-
pended in a smaller volume of 25 µL to maximize signal. One 
microliter, or 2 µL for the in vitro macrophage lysates, was injected 
in pulsed, splitless mode into an Agilent 7890A GC coupled to a 
7000 MS/MS equipped with an Agilent 7693A autosampler oper-
ated in electron capture negative ionization mode, as previously 
described (19). The multiple reaction monitoring transitions 
used in this study were based on transitions initially described by 
Eckstein et al. (20) and have been subsequently optimized. The 
transitions for the derivatized compounds were as follows: TRP 
Q1 = 608.2, Q3 = 270, CE = 5, retention time (RT) = 13.1 min; 
[2H5] TRP Q1 = 613.2, Q3 = 351, CE = 20, RT = 13.1 min; TYR 
Q1 =  585.2, Q3 =  268, CE =  20, RT =  10.9  min; [2H2] TYR 
Q1 = 587.2, Q3 = 436.9, CE = 20, RT = 10.9; KYN Q1 = 612, 
Q3 = 442, CE = 10, RT = 13.0 min; [2H6] KYN Q1 = 618, Q3 = 447, 
CE = 10, RT = 13.0 min; QUIN Q1 = 431.0, Q3 = 298.0, colli-
sion energy (CE) = 10 V, RT = 9.4 min; [2H3] QUIN Q1 = 434.0, 
Q3 = 301.0, CE = 10 V, RT = 9.4 min; 3HK Q1 = 630, Q3 = 219, 
CE  =  15, RT  =  12.9  min. Data were analyzed in a blinded 
fashion using the Agilent MassHunter software, Build B.04 or 
B.05. Samples were injected in a randomized order to minimize 
experimental bias. Each sample was injected at least twice. The 
average of the peak areas from replicate injections were normal-
ized to the average of the heavy standards for each respective 
compound. 3HK was the only compound for which we did not 
have a matching heavy standard; thus, we normalized 3HK to 
[2H6] KYN because of their similar ionization properties. These 
values were fit to the matrix-spiked light standard curves for each 
compound based on the standard addition method.
Flow cytometry
Single-cell suspensions of spleen were obtained by mechanical 
disruption and passage through a 100 µM filter. Cells were then 
stained for fluorescence activated cell sorting (FACS) of dendritic, 
monocytic, and T cell populations, examined on a FACSAriaII 
(BD) at the SKCCC Flow Cytometry Core, or were stained with 
separate panels for extensive flow cytometry phenotyping on an 
LSRFortessa (BD). Representative gating is shown in Figures 
S1 and S2 in Supplementary Material, respectively, and a list of 
macaque antibody clones is provided in Table S1 in Supplementary 
Material. Data were analyzed using the FACSDiVa 6.1.3 (BD) or 
FlowJo (FlowJo) software.
qrT-Pcr
RNA was extracted using the RNeasy Plus Mini kit (Qiagen). 
RNA was reverse transcribed using the High Capacity cDNA 
Kit (Invitrogen Life Technologies; FACS-sorted spleen cells) 
or SuperScript III (Invitrogen Life Technologies; PBMCs and 
in vitro macrophages) on a thermal cycler: 25°C for 10 min, 37°C 
for 120°C min, and 85°C for 5 min.
Because of the small amount of starting material in the sorted 
cells, cDNA from FACS samples were pre-amplified using the 
TaqMan PreAmp Master Mix (Life Technologies) with a pooled 
assay of 0.2× primers for GAPDH and IDO1 on a thermal cycler: 
95°C for 10 min, 95°C for 15 s, 60°C for 4 min, with steps 2–3 
repeated 14 times. Preamplified cDNA was then diluted 1/20 and 
amplified again using the TaqMan Gene Expression Assay (Life 
Technologies).
All other cDNA samples were amplified using the Multiplex 
NoRox PCR Mix (Qiagen): 50°C for 2  min, 95°C for 10  min, 
95°C for 15 s, 60°C for 1 min, with steps 3–4 repeated 40 times. 
GAPDH VIC primer/probe was obtained from Life Technologies 
(Rh02621745_g1). 18S and IDO1 primer/probes were cus-
tom synthesized from Integrated DNA Technologies: IDO1 
(5′-TGCTTTGACGTCCTGCTGG, 5′-TTCCTGTGAGCTGGT 
GGCA, and 5′-TXR—ATGCTGCTCAGTTCCTCCAGGACA — 
IAbRQs); 18S rRNA (5′-TAGAGGGACAAGTGGCGTTC, 
5′-CGCTGAGCCAGTCAGTGT, and 5′-Cy5—AGCAATAACA 
GGTCTGTGATG—BHQ2). Results were analyzed via the 2−ΔΔCt 
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method, with similar results following normalization to either 
18S or GAPDH.
nanostring gene expression analysis
As part of a larger collaborative project, 200  ng of RNA from 
spleens from 58 animals euthanized at various time points 
postinfection were analyzed via a custom NanoString CodeSet for 
116 macaque genes based on rhesus macaque (Macaca mulatta) 
and human sequences, as previously described (21). RNA was 
harvested from 3-mm punches of snap-frozen macaque spleen 
tissue by homogenization in RNA STAT-60 (Isotex Diagnostics) 
in lysing matrix tubes followed by RQ1 DNase treatment 
(Promega) for 1  h at 37°C and purification with the miRVana 
Kit (Invitrogen). Target sequences used in this study are listed 
in Table S2 in Supplementary Material. RNA was hybridized for 
16 h using the CodeSet and analyzed using the nCounter Digital 
Analyzer. Data were normalized to the geometric mean of six 
spiked-in positive controls to correct for assay efficiency. The 
background signal threshold was defined as the average of eight 
spiked-in negative controls +2 SDs following positive control 
correction, a threshold of 30 counts. None of the genes in this 
study had a majority of counts below this threshold. As no single 
housekeeping gene has been proven to be consistently expressed 
across different cell types, cell maturation states, tissue types, 
or disease models (22–26), we performed Kruskal–Wallis non-
parametric analyses of variance on all positive control normal-
ized genes to find the most stably expressed genes across the 
spleen samples (22, 27). We found that the markers CD19, GEM, 
STK25, and CCS were the least varying genes between infection 
groups (Kruskal–Wallis p-values = 0.203, 0.170, 0.121, and 0.111, 
respectively). The geometric mean of these four genes was used 
to normalize the positive control corrected data (26). Trends 
in SIV viral load and IDO1 mRNA expression in spleen were 
independently verified for subsets of the animals by qRT-PCR.
Samples from colon and ileum from 8 additional pigtailed 
macaques (3 procedural controls and 5 chronically infected 
animals euthanized at approximately 84  days postinfection) 
were analyzed in a separate Nanostring CodeSet panel involving 
249 macaque genes based on M. mulatta and human sequences, 
as previously described (28). RNA was extracted from 3-mm 
punches of snap-frozen macaque colon and ileum tissue in a 
manner identical to the spleen above. Colon and ileal RNA were 
supplemented with SUPERase-In RNase Inhibitor for long-term 
storage (1  U/μL final concentration; Life Technologies). Target 
sequences used for the colon and ileum tissue in this study are 
listed in Table S3 in Supplementary Material. Colon and ileum 
transcript RNA data for the five KP genes of interest were normal-
ized to positive control corrected data and then to the geometric 
mean of four housekeeping genes that were not significantly 
different between infection groups in the colon or ileum by 
Kruskal–Wallis: HPRT1, RPL13A, RPS9, and SDHA.
statistical analyses
Spleen metabolite data were analyzed by Mann–Whitney test to 
compare peak values during acute infection (the time point with 
the highest median between days 0 and 14 p.i. for each metabo-
lite, or nadir for TRP), values during asymptomatic infection 
(day 21 p.i.), and all values during chronic infection (between 
days 35 p.i. and terminal) against uninfected controls. p-values 
were Bonferroni adjusted for multiple comparisons.
For plasma metabolites, Wilcoxon signed-rank tests were 
performed on the fold change data to determine whether the 
peak (nadir for TRP) for each animal during acute infection, or 
median values for each animal during asymptomatic and chronic 
infection, were significantly different from their respective pre-
infection values (set as the theoretical value of 1). p-values were 
Bonferroni adjusted for multiple comparisons.
Macrophage metabolites and IDO1 enzyme expression data 
following interferon stimulation were analyzed by Friedman’s 
test for non-parametric, repeated measures data. Longitudinal 
spleen Nanostring nCounter mRNA data were analyzed by 
Kruskal–Wallis test followed by Benjamini–Hochberg false 
discovery rate corrections to account for the number of genes 
examined in the assay. Transcripts that had a significant overall 
Kruskal–Wallis p-value <0.05 following Benjamini–Hochberg 
correction underwent Mann–Whitney tests as described above 
for spleen metabolites. Colon and ileum Nanostring nCounter 
data comparing uninfected and terminally infected animals were 
analyzed by Mann–Whitney test.
Multiple comparison corrections were performed in Microsoft 
Office 2011 Excel. GraphPad Prism 6.0 was used to perform all 
other statistical analyses.
resUlTs
longitudinal Kinetics of KP Metabolites in 
Plasma during siV infection
We first measured KP metabolites in plasma sampled longitudi-
nally from seven macaques following SIV infection. Baseline lev-
els are listed in Table S4 in Supplementary Material. Plasma TRP 
displayed an immediate drop during acute infection (Figure 1A, 
p = 0.048 nadir at day 10 p.i. compared to preinfection values), 
which was sustained throughout asymptomatic and chronic 
infection, significantly so in the latter (p = 0.048).
Levels of KYN, the first major TRP metabolite in the KP, 
inversely mirrored TRP, peaking significantly at day 7 p.i. 
(Figure 1B, p = 0.048), recovering to baseline by day 14 p.i., and 
then resurging during asymptomatic infection (p =  0.048). In 
contrast, 3HK, the downstream metabolite of KYN, paralleled 
TRP and was significantly below preinfection values during 
acute and asymptomatic infection (Figure  1C, p  =  0.048 for 
both analyses). The drop in 3HK levels did not reflect a lack of 
downstream KP activity, however, as levels of the terminal KP 
metabolite QUIN were significantly elevated above baseline 
during acute and asymptomatic infection (Figure 1D, p = 0.048 
for both comparisons). The KYN/TRP ratio was significantly 
elevated throughout all three phases of infection compared to 
preinfection values (Figure 1E, p = 0.048 for all phases).
Serum albumin, which binds >90% of total TRP in the blood, 
was also measured longitudinally in two of the animals. A loss 
in total TRP concentrations along with stable albumin levels 
would result in decreased free TRP available for cellular uptake, 
as cells can only access unbound, free TRP. However, consistent 
FigUre 1 | longitudinal kynurenine pathway metabolites in plasma during siV infection of pigtailed macaques. Seven pigtailed macaques were followed 
longitudinally, with three plasma samples taken prior to infection and seven samples taken postinfection at days 7, 10, 14, 21, 28, 42, and terminally (approximately 
84 dpi). Plasma samples were analyzed for levels of (a) TRP, (B) KYN, (c) 3HK, (D) QUIN, and (e) KYN/TRP ratios. Data are represented as median fold change 
over the average of the preinfection samples for each animal. Error bars represent interquartile ranges. Dotted lines represent the median of preinfection values. Light 
gray shading represents the acute phase of infection (0–14 dpi), and dark gray shading represents the chronic phase of infection (≥35 dpi) in our model. Asterisks (*) 
indicate whether the peak for each animal during acute infection or median values for each animal during asymptomatic and chronic infection was significantly 
different (p < 0.05) from respective preinfection values by Wilcoxon signed-rank test followed by Bonferroni correction.
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with reports of decreased albumin levels in patients (29–31), we 
found that serum albumin levels decreased longitudinally along-
side total TRP in these two animals, potentially minimizing the 
impact on free TRP levels (Figure S3 in Supplementary Material).
longitudinal Kinetics of KP Metabolites in 
spleens of siV-infected Macaques
To determine whether TRP and KP metabolites were similarly 
altered in lymphoid tissue during the course of SIV infection, we 
harvested metabolites from archived spleens from 58 animals 
euthanized at various points throughout infection. Exact numbers 
of animals per time point are listed in Table S5 in Supplementary 
Material.
Notably, TRP levels did not significantly change at any time 
point during infection in the spleen (Figure 2A). However, an 
acute (not significant) drop in median spleen TRP levels at day 4 
p.i. from approximately 100 to 70 µM corresponded with an acute 
increase in KYN levels of approximately 30 µM at this time point 
that was significant (Figure 2B, p = 0.012), indicating a nearly 
perfect 1:1 turnover of TRP into KYN. KYN returned to baseline 
by day 10 p.i. and remained at control levels for the remainder 
of infection. Levels of the downstream metabolites 3HK and 
QUIN peaked slightly later than KYN (Figures 2C,D, p = 0.012 
at day 7 p.i. for both 3HK and QUIN), consistent with a temporal 
progression of degradation down the QUIN axis of the KP during 
infection. Spleen KYN/TRP ratios were similarly elevated during 
acute infection (Figure 2E, p = 0.012 at the peak at day 4 p.i.), but 
actually dropped below baseline during asymptomatic infection 
due to the apparent hyper-recovery of TRP levels at day 21 p.i. 
(p = 0.012 for KYN/TRP ratios at day 21 p.i.). However, neither 
TRP nor any of the KP metabolites or KYN/TRP ratios under-
went any significant changes chronically in the spleen (day 35 p.i. 
and onward). In comparison to the plasma, the spleen therefore 
displayed divergent responses. In particular, plasma KYN/TRP 
ratios, which have been used to predict tissue KP activation, were 
found to overestimate tissue KYN/TRP induction.
systems-Wide comparison of KP 
changes during siV infection
To further understand the dynamics of KP flux occurring at dif-
ferent sites in the body, we compared KP metabolites in plasma 
and spleen with our previous data from CSF and striatal brain 
tissue from these animals (32) (Figures 3A–E). The striatal region 
(a component of the basal ganglia) was chosen because it harbors 
abundant viral replication and demonstrates hallmarks of HIV-
associated neurological disease in both HIV and SIV infection, 
likely in part due to the striatum’s susceptibility to the neurotoxic 
KP metabolites 3HK and QUIN, as well as other sources of oxida-
tive stress and neurotoxicity (33–36). Comparing the brain vs. 
the spleen could thus provide a glimpse into commonalities or 
FigUre 2 | longitudinal analysis of kynurenine pathway (KP) metabolites in spleens from siV-infected pigtailed macaques. Archived spleen samples 
from 58 animals euthanized at various points during infection (ranging from 5 to 9 animals per time point) were analyzed for levels of tryptophan (TRP) and KP 
metabolites: (a) TRP, (B) kynurenine (KYN), (c) 3-hydroxykynurenine (3HK), (D) quinolinic acid (QUIN), and (e) KYN/TRP ratio × 100. Dotted lines represent the 
medians of uninfected controls for each metabolite. Light gray shading represents the acute phase of infection (0–14 dpi), and dark gray shading represents the 
chronic phase of infection (≥35 dpi) in our model. Asterisks (*) indicate whether the peak during acute infection or the total values during asymptomatic or chronic 
infection was significantly different (p < 0.05) from uninfected controls by Mann–Whitney U test followed by Bonferroni correction.
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differences of the diverse tissue morbidities that occur during 
HIV/SIV infection. TRP was largely stable in the tissues (brain 
and spleen), even rising above uninfected levels at certain time 
points despite substantial reductions in the circulating fluids 
(CSF and plasma) (Figure 3A). In contrast, KYN, 3HK, QUIN, 
and KYN/TRP levels diverged according to peripheral vs. central 
lines, with the CNS displaying more robust fold changes than the 
periphery, particularly during chronic infection (Figures 3B–E). 
A noticeable second spike in each animal’s plasma QUIN levels at 
day 14 of acute infection was likely a result of drainage of QUIN 
from the CSF to the plasma (Figure 3D), given that CSF was the 
only site that still had highly elevated levels at this time point, 
highlighting the diversity of tissue sites influencing plasma levels.
Preservation of intracellular TrP levels in 
Macrophages
Given the robust depletion of TRP in the circulating plasma and 
CSF and its relative stability in the spleen and brain tissues, we 
hypothesized that cells within tissues might preserve intracellular 
levels of TRP at the expense of circulating TRP. Macrophages 
and other cells types such as dendritic cells (DCs) are capable of 
suppressing T cell proliferation in vitro via IDO-mediated TRP 
catabolism (37, 38). We chose the macrophage as a representative 
immune cell type to further study in vitro due to its critical impor-
tance in both the brain and periphery during HIV/SIV infection: 
in the brain, macrophages, and the closely related microglia are 
considered to be the single-most important expressers of IDO1 
and downstream KP enzymes due to their ability to produce copi-
ous amounts of the neurotoxin and KP metabolite quinolinic acid 
(39–42). Additionally, a dramatic influx of monocytic lineage 
cells into both the spleen and the brain has been established dur-
ing both acute and chronic infection; these cells are thought to be 
a major driver of HIV/SIV-induced tissue pathology in both sites 
in conjunction with resident macrophages (43–46). Furthermore, 
macrophages are thought to be long-lived viral reservoirs in both 
the spleen and brain, as productively infected macrophages 
can be isolated from both tissue sites in SIV-infected macaques 
throughout infection (47). Thus, we stimulated monocyte-
derived pigtailed macaque macrophages with IFNγ to model the 
in vitro kinetics of KP induction. Supernatant TRP levels dropped 
immediately at 24 h and stayed below control levels (Figure 4A, 
p = 0.006). Corresponding to the drop in TRP in the supernatant, 
the upstream metabolites KYN and 3HK peaked at 24 h, while the 
terminal pathway metabolite QUIN peaked at 48 h (Figure 4B). 
All three metabolites increased significantly above controls dur-
ing the time course (Figure 4B, p = 0.037 for KYN, p = 0.002 for 
3HK, and p = 0.009 for QUIN).
In contrast to the immediate and sustained drop in super-
natant TRP levels, intracellular TRP suffered only slight losses 
that did not reach significance (Figure  4C, p =  0.256). Some 
animal donors even displayed slight increases in TRP, while 
losses in intracellular TRP only occurred in macrophages that 
FigUre 3 | comparison of fold changes in kynurenine pathway metabolites in spleen, brain (striatum), plasma, and csF from siV-infected pigtailed 
macaques. The median fold changes for tryptophan (TRP) (a), kynurenine (KYN) (B), 3HK (c), QUIN (D), and KYN/TRP ratios (e) are overlaid for each respective 
tissue. The horizontal dotted line represents the median of uninfected animals. Light gray shading represents the acute phase of infection (0–14 dpi), and dark gray 
shading represents the chronic phase of infection (≥35 dpi) in our model. Striatal brain and CSF metabolite data have been modified from a previously published 
version (32).
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had depleted >95% of TRP in the supernatant. The maintenance 
of intracellular TRP occurred despite modest increases in 
KYN, 3HK, and QUIN intracellularly (Figure  4D), although 
only QUIN reached significance (p = 0.002). Both supernatant 
and intracellular KYN/TRP ratios were significantly elevated 
(Figure 4E, p = 0.017 and p = 0.006, respectively). In general, 
fold changes for all of the analytes were greater in the supernatant 
than in the lysates, suggesting that the cells actively secreted KP 
metabolites as they were being generated at each step in the 
pathway and replenished intracellular TRP levels at the expense 
of the extracellular milieu.
Finally, we determined the kinetics of IDO1 in response to IFNγ 
and IFNβ, because chronic stimulation of type I IFN responses by 
virus is thought to contribute to chronic induction of IDO1 in 
HIV/SIV infection in addition to IFNγ (48). However, in vitro, 
IFNγ, but not IFNβ, significantly induced IDO1 (Figure  4F, 
p < 0.0001 for IFNγ, p = 0.772 for IFNβ).
Kinetics of KP enzymes during siV 
infection in spleen
In addition to the ability of cells to preserve intracellular levels of 
TRP, a deficiency in IDO1 expression could also explain the lack 
of TRP depletion in tissues. We thus analyzed the expression of 
IDO1 mRNA as well as other key enzymes in the KP in spleens of 
the SIV-infected macaques by NanoString. Paralleling trends in 
the CNS of these animals (32), we found that upstream enzymes 
(IDO1, KMO, and KYNU) displayed significant mRNA upregu-
lation during at least one phase of infection (Figures  5A–C), 
while downstream enzymes (HAAO and QPRT) were either 
downregulated or unchanged (Figures 5D,E). Importantly, IDO1 
was significantly elevated only during acute infection (Figure 5A, 
p =  0.012 at day 4 p.i.), suggesting that while the lack of TRP 
depletion in the spleen during acute infection was due to tissue 
preservation of TRP, chronically it was due to a lack of local IDO1 
induction.
Despite the fact that SIV/HIV can induce IDO1 both directly 
and indirectly (49, 50), spleen SIV RNA peaked later than IDO1 
(days 7 vs. 4 p.i.) during acute infection (p =  0.012 for SIV at 
day 7 p.i.), and remained elevated throughout asymptomatic 
(p = 0.012) and chronic infection (p < 0.001), suggesting that the 
lack of IDO1 induction chronically was not due to a lack of virus 
(Figure 5F). Finally, spleen IDO1 expression correlated strongly 
with spleen IDO1 activity (KYN/TRP ratios) (Figure  6A, 
r  =  0.614, p  <  0.0001). Likewise, IDO1 mRNA in PBMCs 
positively correlated with KYN/TRP ratios in the plasma 
(Figure 6B, p <  0.0001, r =  0.552). These data confirmed the 
close relationship between local IDO1 mRNA levels and local 
IDO1 enzyme activity.
Notably, the lack of chronic IDO1 induction in the spleen was 
not due to a total of peripheral KP activation chronically in our 
model, as ileal and colonic gut tissue from subsequent animals 
demonstrated significant upregulation of IDO1 enzyme mRNA 
during chronic infection (Figure S4 in Supplementary Material; 
p =  0.024 for ileum, p =  0.048 for colon IDO1 expression ter-
minally compared to uninfected). KMO and KYNU expression 
trended upwards during chronic infection in these gut tissues, 
while HAAO and QPRT trended downwards, similar to what 
FigUre 4 | Macaque macrophages maintain intracellular tryptophan (TrP) levels at the expense of extracellular TrP during kynurenine pathway 
activation. Pigtailed macaque macrophages were stimulated with 25 ng/mL IFNγ. After 0, 24, 48, and 72 h, cell-free supernatants were harvested, and cell cultures 
were halved into aliquots for measurements of mRNA (IDO1) and metabolites (TRP, KYN, 3HK, and QUIN). To control for minor well-to-well variations in cell number 
that could affect metabolic turnover, intracellular and extracellular metabolites were normalized to intracellular and extracellular levels of the amino acid tyrosine, 
respectively. Data are represented as means ± SEM of the fold change over unstimulated controls at each time point. The average raw values of each metabolite in 
the unstimulated controls prior to fold change transformation are shown in parentheses on each graph (micromolar for supernatants; pmol/5 × 105 cells for 
intracellular lysates). The dotted lines represent the unstimulated controls at each time point. Results are from six independent experiments from different macaques, 
each with two cell culture technical replicates. (a) TRP levels in macrophage supernatants following IFNγ stimulation. (B) KYN, 3HK, and QUIN levels in macrophage 
supernatants following IFNγ stimulation. (c) Intracellular TRP from harvested cells following IFNγ stimulation. (D) Intracellular metabolites KYN, 3HK, and QUIN from 
harvested cells following IFNγ stimulation. (e) Intracellular and extracellular (supernatant) levels of KYN/TRP ratios, a surrogate for IDO1 enzyme activity, in macaque 
macrophages following IFNγ stimulation. (F) Intracellular IDO1 mRNA expression levels normalized to GAPDH mRNA in macrophage lysates following IFNγ or IFNβ 
stimulation as compared to unstimulated cells. Asterisks (*) represent analytes that were statistically different as a whole across all time points compared to controls 
as analyzed by the Friedman test for non-parametric, repeated measures data.
8
Drewes et al. Kynurenine Pathway Flux in Tissues and Fluids
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 605
was observed in the spleen tissue chronically, although none of 
these trends were statistically significant. The chronic induction 
of IDO1 that we observed in these gut tissues is consistent with 
induction observed by others in gut tissue of SIV-infected rhesus 
macaques and confirms the involvement of the gut in the per-
vasive immunosuppressive features of chronic SIV infection (3).
cell-specific iDO1 expression in 
chronically infected spleen
We next examined whether the lack of IDO1 induction chronically 
in the spleen was due to dysfunction or possibly even depletion of 
antigen-presenting cells (APCs), which are typically the highest 
IDO1 expressers, although the cell-specific contributions during 
HIV/SIV infection are not well established. Splenic mononuclear 
cells (MNCs) were harvested immediately following euthanasia 
in a subsequent group of animals. These chronically infected 
animals were clearly immunocompromised, consistent with our 
model, as levels of CD4+ T cells in their peripheral blood were 
well below baseline during chronic infection (Figure 7A). Splenic 
MNCs from two of these infected animals underwent cell sorting 
by FACS (see Figure S1 in Supplementary Material for sample gat-
ing) and qRT-PCR for cell-specific IDO1 expression. From these 
FACS-sorted cells, we found that myeloid dendritic cells (mDCs) 
and CD14+ monocytes from the chronically infected spleens 
maintained their ability to express high levels of IDO1 mRNA 
(Figure 7B). Our finding that mDCs expressed the highest levels 
of IDO1 is in agreement with a previous study in HIV-infected 
patients in which staining for IDO1 protein in lymph nodes 
mostly colocalized with an mDC-specific marker (2).
Given that the spleen APCs were capable of expressing IDO1, 
we next compared the proportions of various cell types to one 
another by flow cytometry to see whether a relative decline in 
APC number could explain the surprising lack of IDO1 expres-
sion in the chronically infected spleens (representative gating 
is shown in Figure S2 in Supplementary Material). The analysis 
revealed that B, NK, and CD8+ T lymphocytes appeared to be 
present at higher proportions in the spleens of infected animals 
compared to uninfected animals (Figure 7C). However, due to 
losses in splenic CD4+ T cells during infection, the total lym-
phocyte percentage remained the same (Figure 7D, first panel). 
FigUre 5 | IDO1 transcriptional regulation mirrors kynurenine (KYn)/tryptophan (TrP) induction in spleens of siV-infected pigtailed macaques. 
mRNA was harvested from spleens of 58 animals euthanized at various points following SIV infection and analyzed for transcriptional expression of SIV RNA and 
enzymes in the QUIN/NAD+ producing axis of the IDO1 pathway of TRP metabolism. (a) Expression of IDO1, which mediates the oxidative cleavage of the pyrrole 
ring of TRP to form l-formylkynurenine, the precursor to KYN. (B) Expression of kynurenine 3-monooxygenase (KMO), also known as kynurenine 3-hydroxylase, 
which adds a hydroxyl group to KYN to generate 3HK. (c) Expression of kynureninase (KYNU), which catalyzes the hydrolytic cleavage of 3HK to form 3HANA and 
also catalyzes the cleavage of KYN to form anthranilic acid. (D) Expression of 3-hydroxyanthranilate-3,4-dioxygenase (HAAO; also known as 3HAO), which 
oxidatively cleaves the ring of 3HANA to form 2-amino-3-carboxymuconic semialdehyde, the precursor to QUIN. (e) Expression of quinolinate 
phosphoribosyltransferase (QPRT), which mediates the conversion of quinolinic acid into NAD+. (F) Expression of SIV/17E-Fr Gag RNA. The dotted lines in graphs 
(a–e) represent the medians of uninfected controls. Arrows represent the background threshold of the assay. Asterisks (*) represent time points that are significantly 
different (p < 0.05) from uninfected values by Kruskal–Wallis with Bonferroni correction.
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As for APCs, we observed depletion of mDCs (Figure 7D, second 
panel; p = 0.024) but an increase in monocytes (Figure 7D, third 
panel; p = 0.024). Thus, the IDO1 deficiency in the spleen was not 
due to a complete lack of IDO1 expression from APCs nor did it 
appear to be due to a total loss of IDO1-expressing APCs within 
the MNC population, although both factors may still contribute 
to this phenomenon.
DiscUssiOn
Overall, our comprehensive analysis of the KP in various anatomi-
cal sites in SIV-infected macaques reveals tremendous insight 
into the tissue-specific regulation of KP enzymes and metabo-
lites. Despite our hypothesis that inflammation would trigger 
ubiquitous changes in the KP, the tissues and circulating fluids 
displayed highly variable patterns in metabolites and enzymes. 
Most importantly, we did not find any significant reductions in 
TRP in either the spleen or brain at any time point during infec-
tion, despite TRP levels in the plasma and CSF being reduced 
by up to 50%, on par with changes reported in plasma and CSF 
of HIV-infected patients (14, 51, 52). Our in vivo findings were 
further supported by in vitro experiments in which macrophages 
stimulated with IFNγ maintained intracellular TRP levels by 
depleting extracellular TRP.
These data substantiate a growing body of mechanisms 
by which cells and tissues may subvert TRP losses during KP 
activation. For example, IFNγ, which is the major inducer of 
IDO1, also upregulates tryptophanyl-tRNA synthetase (TTS), an 
enzyme that complexes intracellular TRP with its corresponding 
TRP–tRNA (53, 54). Thus, cells exposed to IFNγ may maintain 
or even accumulate intracellular levels of TRP–tRNA complexes 
during KP activation, protecting them from anergy that occurs 
when uncharged tRNAs trigger induction of the GCN2 stress 
kinase pathway (9, 52, 55). Furthermore, given that extracellular 
levels of TRP must be below 3 µM in vitro in order to activate 
the GCN2 stress pathway in T cells (9), and the fact that we 
detected levels of TRP in the tissues well above this concentra-
tion throughout infection (100 µM for spleen, 20 µM for brain), it 
seems unlikely that TRP depletion is a major contributor to T cell 
dysfunction during HIV/SIV infection. These findings question 
some of the fundamental assumptions regarding the role of TRP 
metabolism during immunosuppression and suggest that future 
studies focus more on the KP metabolites themselves.
However, it is important to distinguish between free TRP and 
total TRP, as >90% of the circulating TRP is bound to albumin 
in the blood, and only the free TRP is thought to be accessible to 
cells. Our TRP measurements in this study represent total TRP 
(i.e., albumin-bound +  free TRP). Thus, a 10% change in total 
FigUre 6 | correlations between longitudinal kynurenine (KYn)/tryptophan (TrP) ratios and IDO1 mrna expression in spleen and blood of 
siV-infected pigtailed macaques. (a) Spearman’s rank correlation of splenic IDO1 mRNA expression and splenic KYN/TRP ratios harvested from animals 
euthanized at various points postinfection (n ≥ 5 animals per timepoint). (B) Spearman’s rank correlation of peripheral blood mononuclear cell IDO1 mRNA 
expression and plasma KYN/TRP ratios from five animals followed longitudinally (3 preinfection blood draws averaged together, as well as 7 postinfection blood 
draws at days 7, 10, 14, 21, 28, 42, and approximately 84 dpi, are depicted).
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TRP could deplete all available free TRP. However, multiple stud-
ies have shown that HIV infection is associated with a decrease in 
serum albumin as well (29–31). We similarly found evidence for 
serum albumin depletion in our model, and furthermore, found 
that it paralleled the trends in plasma TRP depletion. These data 
suggest that changes in free TRP in the plasma may actually be 
more stable than previously thought, despite the overall losses 
in total plasma TRP. However, it is still conceivable that in a tis-
sue microenvironment, such as a germinal center, levels of TRP 
may reach dangerously low nadirs, or that chronic exposure to 
slightly lower-than-normal levels of TRP may have long-term 
consequences on T cell function that has not yet been discerned. 
Additionally, perfusion of tissues used in this study may have 
masked any potential changes in TRP levels in extracellular 
spaces. Future studies that shed light on the differences between 
extracellular and intracellular TRP and their respective impacts 
on immune dysfunction are warranted.
In addition to KP metabolites, our results also shed light 
on the transcriptional regulation of KP enzymes during infec-
tion. Concordant with our previous data in brain tissue (32), 
we found that upstream enzymes in the KP (IDO1, KMO, and 
KYNU) displayed more upregulation during acute infection than 
downstream enzymes (HAAO and QPRT). Intriguingly, we also 
found that IDO1 expression in the spleen actually peaked prior to 
peak spleen viral loads (days 4 vs. 7 p.i.) during acute infection. 
This peak in IDO1 at day 4 p.i. coincided with the robust peak in 
IFNβ and multiple IFN-stimulated genes (MxA, IRF7) recently 
published in our model (43). In that study, IFNα expression also 
peaked at day 4 p.i. but was less robustly induced, while IFNγ and 
other known inducers of IDO such as IL6 and TNFα displayed a 
delayed induction as late as days 7 or 14 p.i. (43), suggesting that 
the complex milieu of factors that can stimulate IDO1 expres-
sion are not synchronized during infection. Others have shown 
similar findings during acute infection in plasma of SIV-infected 
macaques, where IDO1 activity (KYN/TRP ratios) peaked before 
viral loads during acute infection and coincided with an acute 
spike in type I IFN levels (56). However, type I IFN is not as 
proficient as type II IFN at inducing IDO1 in vitro (57), which 
we confirmed in our macrophage experiments. Rather than type 
I IFN being responsible for the induction of IDO1 during acute 
infection, it is possible that this earlier peak in IDO1 before virus 
instead reflects rapid downregulation of IDO1 by the same mecha-
nisms involved in the contraction of acute type I IFN responses.
A similar mechanism may be at work during chronic infec-
tion, when IDO1 expression appeared to be suppressed despite 
high levels of spleen viral loads, induction of other KP enzymes 
(e.g., KMO), and presence of mDCs and CD14+ cells capable of 
expressing IDO1. One such potential negative regulator of IDO1 
is the suppressor of cytokine signaling (SOCS) family of proteins. 
SOCS3 in particular has been shown to inhibit Jak/Stat signaling, 
which is required for IDO1 expression, and can also directly target 
IDO1 protein for proteasomal degradation (58). Notably, SOCS3 
has been shown to be elevated in tonsillar tissue of HIV-infected 
patients (59) and in the CNS (60) and spleens of our SIV-infected 
macaques (43). In the SIV-infected spleens, SOCS3 expression 
was shown to be highly expressed not only during acute infection 
but also throughout asymptomatic and chronic infection, dem-
onstrating a strong potential reason for the suppression of IDO1 
despite abundant virus stimuli during chronic infection (43).
Alternatively, expression of IDO1 in at least one DC cell type 
(CD19+ DCs) has been shown to be dependent on CD4+ T cells 
in a murine leukemia virus model of retroviral infection (61). 
Thus, the progressive loss and/or exhaustion of CD4+ T cells in 
the periphery during chronic SIV infection in our model could 
contribute to a reduced production of IDO1 by CD4+ T cell-
dependent DCs (43). However, it is important to note that IDO1 
was significantly upregulated chronically in the colon and ileum, 
where CD4+ T cell depletion is also known to occur (62). This 
discrepancy in IDO1 induction may be a result of differences in 
the cell types and/or cytokines contributing to IDO1 levels in 
FigUre 7 | Myeloid dendritic cells (mDcs) express the highest levels of IDO1 mrna in chronically siV-infected macaque spleen. (a) Absolute CD4+ T 
cell counts in the blood were measured longitudinally using complete blood count and flow cytometry in five animals to confirm immune suppression. (B) Cells were 
teased out of spleen tissue from two animals (designated as the triangle and square, respectively) at 84 days p.i., then sorted by fluorescence-activated cell sorting 
to separate pure populations of pDCs, mDCs, CD14+ monocyte/macrophages, CD4+ T cells, and CD8+ T cells. mRNA was extracted from the isolated cells and 
analyzed for IDO1 expression levels. All data were normalized to internal GAPDH housekeeping mRNA and then to the highest expressing cell type, which was the 
mDC population in both samples, by the 2−ΔΔCt method. Fold change data were transformed to a percentage of the mDC values. Similar results were obtained with 
normalization to 18S ribosomal RNA. (c) Mononuclear cells from all five chronically infected animals as well as three uninfected controls were analyzed by an 
extensive flow cytometry panel for various cell markers. Raw cell percentages are depicted in the left-most panel; median cell percentages are shown in the panel on 
the right. (D) Specific populations of cells were further analyzed by Mann–Whitney test to determine statistical significance.
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different tissue sites. For example, macrophages and microglia 
are thought to be the major producers of IDO1 in the brain 
(41), whereas mDCs may express the highest level of IDO1 in 
the spleen (data shown here) and lymph nodes (2) during HIV/
SIV infection. Conversely, IFNα subtypes are known to differ in 
different tissue sites; such differences could modulate the induc-
tion of IDO1 or IDO1 modulators (63). Future studies will be 
necessary in order to examine the cell-specific requirements of 
IDO and other KP enzyme induction in other peripheral tissue 
sites and during acute vs. chronic infection.
Finally, the results of our study have implications for the treat-
ment of not only HIV but also other diseases in which IDO1 and 
the KP are thought to play a role, such as cancer (64). While our 
results suggest that circulating TRP levels clearly overestimate the 
extent of TRP depletion in the tissues, the KYN/TRP ratio in the 
plasma and the QUIN/TRP ratio in the CSF (32) are consequently 
highly sensitive biomarkers of inflammation and may help to 
identify patients in need of immunotherapy prior to irrepa-
rable tissue damage. Importantly, cART does not fully restore 
peripheral KP metabolites to uninfected levels even in patients 
with undectable viremia (1, 65, 66). IDO1 therefore represents 
a potentially important therapeutic target that could be used in 
conjunction with cART in HIV-infected patients or in conjunc-
tion with chemotherapy in cancer patients (64). However, mixed 
results have been observed following attempts to inhibit IDO1 
with compounds such as the TRP analog, 1-methyl-d-tryptophan 
(d-1MT). For example, administration of d-1MT in conjunction 
with ART during SIV infection of rhesus macaques resulted in 
only a transient improvement in plasma TRP levels but no change 
in plasma KYN levels (67). Our data suggest that reducing the 
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KP metabolite levels is of greater importance than restoring TRP, 
as TRP levels are not at a limiting concentration in the tissues at 
any time point during infection. Boosting immunotherapy in the 
rhesus macaque model by combining d-1MT with anti-CTLA-4 
antibodies and vaccination resulted in severe side effects includ-
ing acute pancreatitis (68). Additionally, the beneficial effects of 
d-1MT may be due to side effects independent of IDO1 (69). 
These non-specific effects and the relatively high micromolar 
concentrations of d-1MT required for an effect render d-1MT an 
unlikely candidate for further applications in patients. As a result, 
second generation inhibitors of IDO1 continue to be developed 
(64). However, inhibition of IDO1 is likely complex due to the 
potential rebound effect of newly uninhibited T cells producing 
IFNγ—a sign that the IDO1 inhibitor is working—that in turn 
could paradoxically induce IDO1 (67). Nevertheless, several 
IDO1 inhibitors including indoximod and epacadostat are now 
undergoing Phase I/II clinical trials in cancer patients in whom 
induction of IDO and resulting evasion of anti-tumoral immune 
responses may play a role (70–72). Advances made toward 
immunotherapy in HIV-infected patients may also benefit cancer 
patients and vice versa.
In conclusion, our study suggests that cellular TRP depletion 
is likely not a major component of IDO1’s immunosuppressive 
capabilities during HIV/SIV infection. In fact, myriad mecha-
nisms exist to stave off TRP starvation, including (1) downregu-
lation of IDO1 expression by SOCS3; (2) upregulation of TTS 
to allow cells to store TRP complexed to the TRP–tRNA during 
IFNγ stimulation; (3) reductions in serum albumin during infec-
tion, which alleviates deficits in free TRP; and (4) the relatively 
high levels of TRP in the tissues, making the likelihood that TRP 
would be depleted below the necessary <3 µM relatively unlikely. 
Clearly, these findings will need to be confirmed in other models, 
but nevertheless they shed light on how cells and tissues prioritize 
TRP use in the face of KP activation.
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